{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:39Z","timestamp":1786986879603,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010875","name":"Amgen Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015993","name":"Kowa Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018679","name":"HLS Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.cjco.2022.03.003","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T21:06:38Z","timestamp":1647032798000},"page":"558-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study"],"prefix":"10.1016","volume":"4","author":[{"given":"Milan","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.B. John","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajvi J.","family":"Wani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineeta","family":"Ahooja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Manjoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Shekhar","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin S.","family":"Mackinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2022.03.003_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2022.03.003_bib4","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2022.03.003_bib5","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2022.03.003_bib6","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.1410","article-title":"Low-density lipoprotein cholesterol goal attainment and treatment patterns in a cohort of > 143,000 patients with atherosclerotic cardiovascular disease in Ontario, Canada","author":"Fairbairn","year":"2020"},{"key":"10.1016\/j.cjco.2022.03.003_bib8","doi-asserted-by":"crossref","unstructured":"Rogoza R, Oh P, Goeree P, et al. Patterns of low-density lipoprotein cholesterol management and goal attainment in patients with atherosclerotic cardiovascular disease 65 years and older from Alberta and Ontario. Paper presented at: Canadian Cardiovascular Congress. October 21-24, 2020. Virtual.","DOI":"10.1016\/j.cjca.2020.07.057"},{"issue":"11","key":"10.1016\/j.cjco.2022.03.003_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0735-1097(20)30671-9","article-title":"Lipid-lowering therapy patterns and low-density lipoprotein-cholesterol management among patients with acute myocardial infarction in Alberta, Canada","volume":"75","author":"Scory","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib10","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jacc.2020.07.033","article-title":"Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention","volume":"76","author":"Sud","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib11","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib12","unstructured":"Amgen Canada Inc. Repatha (evolocumab) product monograph. Available at: https:\/\/www.amgen.ca\/\u223c\/media\/ae162719487c459391bd1b1584a25ead.ashx. Accessed February 18, 2022."},{"key":"10.1016\/j.cjco.2022.03.003_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2022.03.003_bib14","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia","volume":"74","author":"Koren","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25 suppl 2","key":"10.1016\/j.cjco.2022.03.003_bib15","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2022.03.003_bib16","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1080\/03007995.2018.1477747","article-title":"A\u00a0systematic literature review comparing methods for the measurement of patient persistence and adherence","volume":"34","author":"Forbes","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cjco.2022.03.003_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.cjco.2022.03.003_bib18","first-page":"3013","article-title":"Does evolocumab use in Europe match 2019 ESC\/EAS lipid guidelines? Results from the HEYMANS study [abstract]","volume":"41","author":"Ray","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2022.03.003_bib19","first-page":"884","article-title":"Treatment and low-density lipoprotein cholesterol management in patients diagnosed with clinical atherosclerotic cardiovascular disease in Alberta","volume":"35","author":"Chen","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib20","first-page":"1004","article-title":"Attainment of recommended lipid targets in patients with familial hypercholesterolemia: real-world experience with PCSK9 inhibitors","volume":"34","author":"Razek","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/HCO.0000000000000424","article-title":"The emerging role of proprotein convertase subtilisin\/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience","volume":"32","author":"Pandey","year":"2017","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib22","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamacardio.2018.4178","article-title":"Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: an analysis of FOURIER trial data","volume":"4","author":"Qamar","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0735-1097(20)30799-3","article-title":"Lipid testing, lipid modifying therapy and PCSK9 inhibitor eligibility in 22,603 patients with incident acute coronary syndrome","volume":"75","author":"Sarak","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","article-title":"Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries","volume":"2","author":"Colantonio","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjco.2022.03.003_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2017.05.018","article-title":"Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care","volume":"263","author":"Guglielmi","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjco.2022.03.003_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5554","article-title":"Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and\/or ezetimibe","volume":"1","author":"Khunti","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cjco.2022.03.003_bib29","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1517\/14656560903376186","article-title":"Non-adherence to statin therapy: a major challenge for preventive cardiology","volume":"10","author":"Bates","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cjco.2022.03.003_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146272","article-title":"Understanding statin non-adherence: knowing which perceptions and experiences matter to different patients","volume":"11","author":"Wouters","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cjco.2022.03.003_bib31","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/CIRCULATIONAHA.116.025233","article-title":"Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies","volume":"135","author":"Toth","year":"2017","journal-title":"Circulation"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X22000518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X22000518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:07:33Z","timestamp":1762902453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X22000518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2589790X22000518"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2022.03.003","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2022.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}